

Supplementary File 3: Additional drug resistance in the study population

DST results at baseline. Missingness documents that a sample was not tested against a particular drug. Col.- column, DST- drug sensitivity testing, No.- number

Exposure variables		England		London	
		No.	Col. %	No.	Col. %
Overall		1,228	100	626	100
Ethambutol	Sensitive	1,201	97.8	611	97.6
	Resistant	23	1.9	15	2.4
	Missing	4	0.3	0	0.0
Pyrazinamide	Sensitive	1,210	98.5	616	98.4
	Resistant	13	1.1	9	1.4
	Missing	5	0.4	1	0.2
Streptomycin	Sensitive	638	52.0	422	67.4
	Resistant	294	23.9	139	22.2
	Missing	296	24.1	65	10.4
Amikacin	Sensitive	111	9.0	55	8.8
	Resistant	0	0.0	0	0.0
	Missing	1,117	91.0	571	91.2
Kanamycin	Sensitive	89	7.2	37	5.9
	Resistant	0	0.0	0	0.0
	Missing	1,139	92.8	589	94.1
Capreomycin	Sensitive	108	8.8	54	8.6
	Resistant	2	0.2	1	0.2
	Missing	1,118	91.0	571	91.2
Ciprofloxacin	Sensitive	339	27.6	19	3.0
	Resistant	4	0.3	0	0.0
	Missing	885	72.1	607	97.0
Ofloxacin	Sensitive	101	8.2	47	7.5
	Resistant	0	0.0	0	0.0
	Missing	1,127	91.8	579	92.5
Moxifloxacin	Sensitive	102	8.3	48	7.7
	Resistant	0	0.0	0	0.0
	Missing	1,126	91.7	578	92.3
Azithromycin	Sensitive	151	12.3	0	0.0
	Resistant	1	0.1	0	0.0
	Missing	1,076	87.6	626	100.0
Clarithromycin	Sensitive	332	27.0	10	1.6
	Resistant	13	1.1	11	1.8
	Missing	883	71.9	605	96.6
Ethionamide	Sensitive	68	5.5	32	5.1
	Resistant	39	3.2	22	3.5
	Missing	1,121	91.3	572	91.4
Prothionamide	Sensitive	56	4.6	19	3.0
	Resistant	34	2.8	18	2.9
	Missing	1,138	92.7	589	94.1

Supplementary File 3: continued

Exposure variables		England		London	
		No.	Col. %	No.	Col. %
Cycloserine	Sensitive	18	1.5	17	2.7
	Resistant	1	0.1	1	0.2
	Missing	1,209	98.5	608	97.1
Para-aminosalicylic acid	Sensitive	9	0.7	4	0.6
	Resistant	2	0.2	1	0.2
	Missing	1,217	99.1	621	99.2
Linezolid	Sensitive	69	5.6	31	5.0
	Resistant	0	0.0	0	0.0
	Missing	1,159	94.4	595	95.0
Rifabutin	Sensitive	171	13.9	18	2.9
	Resistant	0	0.0	0	0.0
	Missing	1,057	86.1	608	97.1